This proposal is focused on developing EZH2 inhibitors, HDAC inhibitors, dual EZH2-HDAC inhibitors and PROTACS in pursuit of extracting long term therapeutic benefits in IPF. To be more precise and specific, this proposal may validate the revelations regarding the emergence of EZH2 and HDAC as prudent targets for the design of anti-IPF agents. Also, a successful implementation of this proposal may open an avenue for the development of multitargeting agents as well as degraders in the near future and researchers might channelize their efforts in this direction. This can be particularly beneficial for the medicinal chemist who has been striving hard to deal with notorious drug resistance issue via single target inhibitors. To add on, the preliminary biological evaluation results holds huge enough promise and optimism to expand this research proposal in future involving detailed preclinical and clinical investigation. It is noteworthy to mention that the positive outcome of this proposed investigation may imbibe a high degree of fascination among the budding and brightest science graduates towards the rational drug design approach and might also inspire them to utilize the concepts of fragment based drug design to develop potent anti- IPF agents. Overall, the attempts in the longer run are focused on extracting societal benefits through this research endeavour for the academicians, researchers, young scientists and the pharmaceutical industrial sector.
|Effective start/end date||8/1/22 → 7/31/23|
- Idiopathic pulmonary fibrosis
- drug design
- human fibroblasts
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.